Glioblastoma (GBM) represents the most common malignant primary brain neoplasm in adult patients with a median overall survival (OS) in a modern US population-based cancer registry data Surveillance, Epidemiology, and End Results (SEER) of 11 and 14.6 months based on standard of care therapy (1,2). Despite advances in treatment, GBM (WHO grade IV) is associated with considerable morbidity and mortality as compared with other malignancies.

Recurrent disease is nearly inevitable for all patients diagnosed with this cancer. Once a GBM patient experiences relapse and/or recurrence, they have a poor median OS with modern phase 3 study with OS ranging from 8 to 9 months even with utilization of FDA approved standard of care treatment regimens (3). Bevacizumab, anti-vascular endothelial growth factor-A (VEGF-A) antibody, was initially promising given the highly vascularized nature of GBM and the phase 2 studies by Taal et al. and Friedman et al. demonstrated favorable results (4,5). In particular, the BELOB study, a phase 2 study designed to compare bevacizumab alone versus lomustine alone and lomustine in combination with bevacizumab, showed an improved 9-month OS survival in the combination group receiving bevacizumab with lomustine in comparison to lomustine alone (59% versus 38%, respectively) (5). These results prompted the phase 3 EORTC trial randomizing patients to either lomustine alone or bevacizumab in combination with lomustine (3). Despite the initial phase 2 findings that the combination improved outcomes, this phase 3 study failed to show superiority of the combination in comparison to lomustine monotherapy with median OS of 9.1 months (95% CI, 8.1–10.1 months) in the combination group and 8.6 months (95% CI, 7.6–10.4 months) in the monotherapy group (3). Neuro-oncologists have sought the appropriate anti-angiogenic agent or combination of anti-angiogenic and chemotherapy for the treatment of recurrent GBM, but phase 3 studies have remained unable to improve OS outcomes (6). This holds true for phase 3 studies in newly diagnosed GBM patients as the addition of bevacizumab to standard of care concurrent radiation therapy with temozolomide followed by adjuvant temozolomide failed to extend median OS (7-9). Beyond bevacizumab, investigators have studied anti-angiogenic in phase 3 trials including cilengitide, intravenous αv integrin inhibitor, and cediranib, an orally available pan-VEGF receptor tyrosine kinase inhibitor, but remarkable results have failed to be achieved for these studies in recurrent and newly diagnosed GBM (10-12). Theories point to the fact that while VEGF receptor is responsible for angiogenic growth in GBM that there are other signaling pathways that can be co-opted to promote growth that are complementary or agnostic to angiogenesis (13).

The REGOMA trial published by Lombardi and colleagues utilizes regorafenib, an agent that targets signaling pathways involved in angiogenesis and other growth pathways thereby confronting the challenges that bevacizumab faced in the treatment of GBM (14). Regorafenib is an orally available multi-kinase inhibitor that targets angiogenic, stromal and oncogenic receptor tyrosine kinases (15,16). Tyrosine receptor kinases targeted include
being examples of these observations. Therefore, based on multicenter, open-label, randomized, controlled phase 2 trial, there is renewed hope for new therapeutics utilizing anti-angiogenics in relapsed GBM.

For the neuro-oncology community, a successful phase 2 clinical trial in relapsed GBM is often met with a balance of optimism and skepticism. Experiences of promising therapeutic agents from phase 2 clinical trials such as the BELOB trial comparing bevacizumab monotherapy, lomustine monotherapy, and combination of bevacizumab with lomustine and subsequent lack of congruence with a similar phase 3 randomized controlled trial leads neuro-oncologists to take pause at successful phase 2 studies. Particular to REGOMA, while some patient characteristics were balanced such as ECOG performance status and IDH mutation status, there was a trend towards more favorable patient characteristics in the regorafenib group. These were younger age, higher percentage of methylated MGMT promoter status, longer median time to relapse from initial surgery and/or radiation therapy, and lower corticosteroid usage at time of enrollment. This puts into question whether the regorafenib group has more favorable prognostic factors in comparison to control group.

This apparent imbalance between the control and experimental groups is also highlighted in regards to treatment regimens after progression on this study. A higher percentage of patients in the regorafenib group received third-line therapy than patients in the lomustine group. One rationale for this observation is that more favorable prognostic factors evidenced in the regorafenib group at the time of enrollment allowed them to move forward with more therapeutics even in the third-line setting.

The obvious comparator to this phase 2 study is the BELOB study that this editorial continues to reference (5). Median OS of lomustine at a similar dose of 110 mg/m² in the BELOB study was 8 months (95% CI, 6–11 months) and in the following phase 3 study comparing single agent lomustine to combination lomustine and bevacizumab, the median OS in the lomustine monotherapy (110 mg/m²) was 8.6 months (95% CI, 7.6–10.4 months) (3). It is important to note that this median OS for lomustine monotherapy exhibited in the phase 3 study of lomustine monotherapy in comparison to lomustine and bevacizumab combination therapy is also superior to the lomustine monotherapy arm in REGOMA. The striking inferiority of lomustine monotherapy in the REGOMA study provides reflection of whether a larger randomized phase 3 study can aid in understanding whether the signal towards improvement
is real for the regorafenib treated group (Table 1). Other studies in recurrent GBM have shown similar median OS for lomustine monotherapy. The phase 3 trial of enzastaurin, an oral serine/threonine kinase inhibitor, in comparison to control group of lomustine (100 to 130 mg/m² on day 1 in 6-week cycle) demonstrated a median OS [7.1 months (95% CI, 6.0–8.8 months)] more comparable to BELOB and this was conducted before widespread use of bevacizumab as a salvage treatment (24). The phase 3 trial of cediranib in comparison to combination cediranib with lomustine and lomustine monotherapy further documented a median OS of 9.8 months in the lomustine monotherapy group (12). Based on this historical data with lomustine monotherapy in recurrent GBM, one must question the obvious inferiority of lomustine monotherapy in the REGOMA study.

Given the obvious and apparent toxicities of regorafenib with skin reactions such as hand-foot-skin syndrome, it will be challenging to proceed with a blinded study. Moving forward, it will benefit investigators in the phase 3 of regorafenib to power the study appropriately so that a true understanding of the control/comparator group can be demonstrated. The authors acknowledge these shortcomings in this study and concede that moving forward the study needs to have more balanced patient characteristics, increased power, and independent centralized review of magnetic resonance imaging (MRI) imaging in the assessment of progression.

In conclusion, results from the study by Lombardi and colleagues are promising and give hope to the use of anti-angiogenics in relapsed GBM. Given the side effect profile of this targeted agent, investigators should choose the appropriate health-related quality of life patient-reported outcomes instruments to capture the patient and caregiver experience with an agent such as regorafenib. Lombardi and colleagues conclude in their manuscript that the results of REGOMA warrants investigation of regorafenib in a larger phase 3 clinical trial. While this is the logical next step for the development of regorafenib as a potential therapeutic in recurrent GBM population, it is important to advise the potential investigators of a future phase 3 trial for regorafenib in recurrent GBM to design carefully the power of the study, to understand the balance of patient characteristics between the control and experimental groups, and to select appropriately the control therapeutic agent.

### Acknowledgments

None.

### Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

### References


---

**Table 1** Comparison of phase 2 and 3 recurrent GBM trials with lomustine monotherapy control groups

<table>
<thead>
<tr>
<th>Experimental agent and/or combination (study)</th>
<th>Enzastaurin (24)</th>
<th>Cediranib* or cediranib + lomustine (12)</th>
<th>Bevacizumab** or bevacizumab + lomustine (5)</th>
<th>Bevacizumab + lomustine (3)</th>
<th>Regorafenib (14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study name</td>
<td>n/a</td>
<td>n/a</td>
<td>BELOB</td>
<td>EORTC 26101</td>
<td>REGOMA</td>
</tr>
<tr>
<td>Randomization</td>
<td>2:1</td>
<td>2:2:1</td>
<td>1:1:1</td>
<td>2:1</td>
<td>1:1</td>
</tr>
<tr>
<td>Number</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lomustine monotherapy</td>
<td>92</td>
<td>65</td>
<td>46</td>
<td>149</td>
<td>60</td>
</tr>
<tr>
<td>Experimental group</td>
<td>174</td>
<td>131</td>
<td>50</td>
<td>288</td>
<td>59</td>
</tr>
<tr>
<td>Median overall survival (95% CI) (months)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lomustine monotherapy group</td>
<td>7.1 (6.0–8.8)</td>
<td>9.8</td>
<td>8 [6–11]</td>
<td>8.6 (7.6–10.4)</td>
<td>5.6 (4.7–7.3)</td>
</tr>
<tr>
<td>Experimental group</td>
<td>6.6 (5.2–7.8)</td>
<td>8.0</td>
<td>8 [6–9]</td>
<td>9.1 (8.1–10.1)</td>
<td>7.4 (5.8–12.0)</td>
</tr>
</tbody>
</table>

* only reporting cediranib monotherapy group in this table; ** only reporting bevacizumab monotherapy group in this table. n/a, not available.


Cite this article as: Peters KB. Revisiting anti-angiogenic therapy for recurrent glioblastoma. Transl Cancer Res 2019. doi: 10.21037/tcr.2019.05.25